Home Clinical Topics Medications

Medications

Study shows reduced risk of cardiovascular disease during times of bereavement with daily aspirin...

A study published in the American Heart Journal explored the effects of aspirin and low dose metoprolol intake during early bereavement periods. Times of bereavement are often associated with an “increased risk of cardiovascular disease,”...

New vaccine eliminated breast cancer in first human patient

A vaccine being developed in the Mayo Clinic in Jacksonville, Florida is aimed at preventing new cases of ovarian and breast cancer and even recurring cases of these cancers. The vaccine is currently being tested,...

New treatment for peanut allergy in children

The U.S. Food and Drug Administration (FDA) recently approved Aimmune Therapeutics’ Palforzia for children suffering from peanut allergy. Palforzia is intended to help “allergic reactions, including anaphylaxis, that may occur with accidental exposure...

Ultrasound-guided I.V. catheter insertion

Standardized protocols and education can improve patient safety, reduce costs, and enhance nursing practice. Takeaways: Achieving peripheral I.V. access can be difficult, even for experienced clinicians. Approximately 90% of hospitalized patients require some form of...

FDA launches mobile app on antiretrovirals

On Jan. 29, the FDA launched an interactive database that will offer a wealth of critical information about antiretrovirals eligible for purchase under the President’s Emergency Plan for AIDS Relief (PEPFAR) program. Read more https://www.fda.gov/news-events/press-announcements/fda-launches-mobile-friendly-database-information-life-saving-hiv-drugs-part-ongoing-mission-empower.

New treatment for advanced epithelioid sarcoma

The U.S. Food and Drug Administration (FDA) recently approved Epizyme, Inc’s tazemetostat (TAZVERIK) for the treatment of adult and pediatric patients with metastatic or advanced epithelioid sarcoma (AES). AES is a rare sarcoma that affects...

Survey reveals 40% of patients with MS stop taking medications because of cost

A new survey conducted by the National MS Society (NMSS) reveals that 40% of respondents “altered or stopped taking their medication” due to the medication(s) high costs. NMSS also highlights that in 2019, the...

First FDA approved treatment for thyroid eye disease

The U.S. Food and Drug Administration (FDA) recently approved Horizon Therapeutics Ireland DAC’s teprotumumab-trbw (Tepezza) as the first FDA-approved treatment for adults with thyroid eye disease (TED). TED is a rare disorder which causes the...

Making diabetes education more effective

Is individual or group education most effective for patients with diabetes? A systematic review in the Journal of Nursing Scholarship indicates that each has a role. Individual education is most effective in reducing HbA1c, and...

FDA to host meeting on the development of products for rare diseases

On February 24, the U.S. Food and Drug Administration (FDA) is hosting a public meeting to celebrate FDA Rare Disease Day 2020 which will focus on what the future holds for the product development...

Study fails to show benefit of adding vitamin C to treatment of septic shock

A study recently published in the Journal of the American Medial Association aimed to examine if a treatment combination of vitamin C, hydrocortisone, and thiamine would lead to a “rapid resolution of septic shock”...

First targeted therapy for rare mutation of gastrointestinal stromal tumors

The U.S. Food and Drug Administration (FDA) recently announced the approval of Blueprint Medicines Corporation’s avapritinib (Ayvakit) for the treatment of adult patients with metastatic gastrointestinal stromal tumor (GIST) with the “platelet-derived growth factor...

First FDA-approved treatment for preventing Ebola virus

In late December 2019, the U.S. Food and Drug Administration (FDA) announced the approval of Merck’s Ervebo, the first FDA-approved vaccine to prevent Ebola virus disease. The FDA Deputy Commissioner for Policy, Legislation, and International...